Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 406 to 420 of 795 results for mental health

  1. Pharmacological interventions for anxiety disorders in people with learning disabilities who have autism:- What is the clinical and cost effectiveness and safety of pharmacological interventions for anxiety disorders in people with learning disabilities who have autism?

    side effects and effectiveness may contribute to the under-treatment of mental health problems in people with learning disabilities who...

  2. Shared decision making (NG197)

    This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.

  3. Sunlight exposure: risks and benefits (NG34)

    This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

  4. What is the efficacy and cost effectiveness of rehabilitation services compared with treatment as usual for people with complex psychosis with residual disability, who are leaving early intervention services?

    complex psychosis. Qualitative evidence also showed that people with severe mental illness value rehabilitation. There was moderate...

  5. Multiple sclerosis (QS108)

    This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.

  6. Cannabidiol for treating seizures caused by tuberous sclerosis complex (TA873)

    Evidence-based recommendations on cannabidiol (Epidyolex) for treating seizures caused by tuberous sclerosis complex.

  7. Diarrhoea and vomiting caused by gastroenteritis in under 5s: diagnosis and management (CG84)

    This guideline covers diagnosing, managing and referring infants and young children younger than 5 years who present with acute diarrhoea (lasting up to 14 days) with or without vomiting. It aims to improve the diagnosis and management of infective gastroenteritis and appropriate escalation of care.

  8. Medicines management for people receiving social care in the community (QS171)

    This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.

  9. Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)

    Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.

  10. Rapid tranquillisation in mental health settings: promethazine hydrochloride (ESUOM28)

    This evidence summary has been updated and replaced by NICE guideline NG10.

  11. Percutaneous transforaminal endoscopic lumbar discectomy for sciatica (HTG412)

    Evidence-based recommendations on percutaneous transforaminal endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.

  12. Prosthetic intervertebral disc replacement in the cervical spine (HTG217)

    Evidence-based recommendations on prosthetic intervertebral disc replacement in the cervical spine. This involves removing the damaged disc and inserting an artificial disc in its place.

  13. Pneumonia: diagnosis and management (NG250)

    This guideline covers diagnosing, assessing, and treating community-acquired and hospital-acquired pneumonia, including bacterial pneumonia secondary to COVID-19, in babies over 1 month (corrected gestational age), children, young people and adults. It aims to optimise antibiotic use and reduce antibiotic resistance.

  14. Intrapartum care: existing medical conditions and obstetric complications (QS192)

    This quality standard covers care during labour and birth for women who need extra support because they have a medical condition or complications in their current or previous pregnancy. It also covers women who have had no antenatal care. It describes high-quality care in priority areas for improvement. It does not cover the antenatal and postnatal care of pregnant women with mental health conditions, hypertension in pregnancy, diabetes in pregnancy or the organisation of care for pregnant women with complex social factors.

  15. Hearing loss in adults: assessment and management (NG98)

    This guideline covers some aspects of assessing and managing hearing loss in primary, community and secondary care. It aims to improve the quality of life for adults with hearing loss by advising healthcare staff on assessing hearing difficulties, managing earwax and referring people for audiological or specialist assessment and management.